Phio Pharmaceuticals (PHIO) director Freeman received 1,000 shares
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
Jonathan E Freeman (director at Phio Pharmaceuticals Corp., PHIO) reported that they received 1,000 shares on Sep 11, 2024. After these transactions the filing shows 1,000 shares held directly.
- Reporting person
- Freeman Jonathan E
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Sep 11, 2024 | Grant or award (A) | Common Stock, $0.0001 par value1, 2 | +1,000 | - | - | 1,000 direct |
Holdings before and after
- Common Stock, $0.0001 par value: 0 to 1,000 direct
Footnotes from the filing
- 1. Represents shares underlying a restricted stock unit, which shares will vest on the first anniversary of the grant.
- 2. Includes shares of common stock underlying unvested restricted stock units.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Freeman report in this PHIO Form 4?
Jonathan E Freeman (director at Phio Pharmaceuticals Corp., PHIO) reported that they received 1,000 shares on Sep 11, 2024. After these transactions the filing shows 1,000 shares held directly.
How many PHIO shares does Freeman hold after this filing?
The filing shows 1,000 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for PHIO
Earlier insider filings at PHIO
- Sep 13, 2024Chairman, Pres & CEO Bitterman Robert J was granted 15,500 shares, increasing direct ownership by 665% to 17,832 units (SEC Form 4)
- Sep 12, 2024Director Lockshin Curtis was granted 2,000 shares (SEC Form 4)
- Sep 12, 2024Director Ferrara Robert L was granted 10,000 shares (SEC Form 4)
- Sep 12, 2024Director Bradford Patricia A was granted 8,000 shares (SEC Form 4)
- Aug 15, 2024VP, Chief Financial Officer Infarinato Robert M. was granted 8,000 shares (SEC Form 4)
Keep researching PHIO
- PHIO insider tradesEvery buy and sale reported by Phio Pharmaceuticals Corp. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- PHIO earnings historyPast Phio Pharmaceuticals Corp. earnings releases, newest first.
- PHIO financial statementsRevenue, profit, cash flow and balance sheet from Phio Pharmaceuticals Corp.'s SEC filings.
Quantisnow market dataNASDAQ
PHIO
Phio Pharmaceuticals Corp.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for PHIO
Full PHIO profile on Quantisnow Follow PHIO and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time